ENDRA Life Sciences

ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company is headquartered in Ann Arbor, Michigan and currently employs 11 full-time employees. The company went IPO on 2017-06-28. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.